New FDA Policy On Diagnostics Studies “Fills A Big Gap,” CDRH Chief Says
This article was originally published in The Pink Sheet Daily
The guidance “is intended to describe some statistically appropriate practices for reporting results from different studies evaluating diagnostic tests and identify some common inappropriate practices,” FDA states in the document.
You may also be interested in...
Avastin is one example where the drug’s mechanism of action may be too broad to warrant a companion diagnostic, CEO Levinson says.
The US agency sent a letter to health-care providers spotlighting its analysis of the increasing numbers of adverse events linked to surgical staplers and implantable staples, and its plans for a draft guidance on labeling and an advisory panel meeting to consider a 510(k) requirement for the products.